Recent advancement on PD-L1 expression quantification: the radiologist perspective on CT-guided FNAC | Zendy

Silvia Casale | Zendy; Chandra Bortolotto | Zendy; Giulia Maria Stella | Zendy; Andrea Riccardo Filippi | Zendy; Salvatore Gitto | Zendy; Olivia Maria Bottinelli | Zendy; Sergio Carnevale | Zendy; Patrizia Morbini | Zendy; Lorenzo Preda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Recent advancement on PD-L1 expression quantification: the radiologist perspective on CT-guided FNAC

Author(s) -

Silvia Casale,

Chandra Bortolotto,

Giulia Maria Stella,

Andrea Riccardo Filippi,

Salvatore Gitto,

Olivia Maria Bottinelli,

Sergio Carnevale,

Patrizia Morbini,

Lorenzo Preda

Publication year - 2021

Publication title -

diagnostic and interventional radiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.754

H-Index - 43

eISSN - 1305-3612

pISSN - 1305-3825

DOI - 10.5152/dir.2021.19545

Subject(s) - durvalumab , atezolizumab , medicine , nivolumab , avelumab , pembrolizumab , lung cancer , immunotherapy , immune system , immune checkpoint , pd l1 , cancer research , cancer , oncology , immunology

We aimed to evaluate the feasibility, accuracy, and safety of Programmed Death-1/ Programmed Death-Ligand 1 (PD-1/ PD-L1) expression quantification in cytology cell-block samples obtained through transthoracic CT-guided fine-needle aspiration cytology (FNAC) from the interventional radiologist's perspective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research